
Opinion|Videos|June 12, 2025
Seamless Transitions: Managing the Inpatient to Outpatient Care Continuum
Panelists discuss how best practices for transitioning from inpatient to outpatient care involve clear communication, regular monitoring, and adjusted visit frequencies, while addressing challenges such as care coordination and patient adherence to follow-up plans.
Advertisement
Episodes in this series

Summary for Physicians:
Best Practices for Transitioning From Inpatient to Outpatient Care:
- Clear communication:
- Ensure care coordination between inpatient and outpatient teams for a smooth transition.
- Provide detailed discharge instructions, including follow-up plans, medications, and warning signs of complications.
- Outpatient visit frequency:
- Initially, schedule visits weekly or biweekly post discharge for close monitoring.
- After stabilization, transition to monthly visits, adjusting based on patient condition.
- Key monitoring strategies:
- Monitor for toxicity (eg, cytokine release syndrome, neurological issues) and infection risks
- Regular assessments of vital signs, lab tests, and adverse effect management
- Ensure patient adherence to treatment protocols and ongoing symptom tracking
Challenges:
Coordinating care across multiple providers and ensuring patient adherence with follow-up plans.
Advertisement
Related to this article

Ralph V. Boccia, MD, FACP, discussed educating hospital teams and using tocilizumab to manage bispecific toxicities when patients need admission.

Martin Gleave, CM, MD, FRCSC, FACS, explained how the GUNS trial is using tumor genomics to guide neoadjuvant therapy in high-risk prostate cancer.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Ralph V. Boccia, MD, FACP, noted how designated hospitals and a 24/7 on-call team support emergencies during bispecific step-up dosing.

Arturo Loaiza-Bonilla, MD, MSEd, FACP, co-founder of Massive Bio and system-wide chief of hematology and oncology at St. Luke’s, explains how AI is matching patients to clinical trials, where the technology falls short, and why he left academia to build what oncology was missing.

The FDA granted RMAT and fast track designations to prizlon-cel, a CD20/CD19 CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

Ralph V. Boccia, MD, FACP, explained the caregiver’s role in monitoring and reporting during bispecific antibody step-up dosing.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Perioperative Durvalumab/Enfortumab Vedotin in MIBC
2
Subsequent Therapy May Have Narrowed the Overall Survival Gap in LITESPARK-011
3
Managing Emergencies During Outpatient Bispecific Step-Up Dosing
4
ACS Updates Prostate Cancer Screening Guideline With Risk-Based PSA Intervals
5

